$CVSI
CV Sciences, Inc.

2023 Q3 Form 10-Q Financial Statement

#000151096423000032 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $4.089M $3.966M $4.138M
YoY Change 9.01% -4.16% -19.31%
Cost Of Revenue $2.246M $2.248M $2.868M
YoY Change 2.6% -21.62% 1.06%
Gross Profit $1.843M $1.718M $1.270M
YoY Change 17.99% 35.28% -44.54%
Gross Profit Margin 45.07% 43.32% 30.69%
Selling, General & Admin $2.240M $2.758M $3.483M
YoY Change -7.05% -20.82% -37.52%
% of Gross Profit 121.54% 160.54% 274.25%
Research & Development $40.00K $36.00K $102.0K
YoY Change -9.09% -64.71% -54.67%
% of Gross Profit 2.17% 2.1% 8.03%
Depreciation & Amortization $58.00K $59.00K $343.0K
YoY Change -7.94% -82.8% 73.23%
% of Gross Profit 3.15% 3.43% 27.01%
Operating Expenses $2.280M $2.794M $3.585M
YoY Change -7.09% -22.06% -38.19%
Operating Profit -$437.0K -$1.076M -$2.315M
YoY Change -51.01% -53.52% -34.05%
Interest Expense -$10.00K -$209.0K -$336.0K
YoY Change -96.24% -37.8% 3633.33%
% of Operating Profit
Other Income/Expense, Net -$10.00K -$209.0K -$336.0K
YoY Change -96.24% -37.8%
Pretax Income -$447.0K -$1.285M -$2.651M
YoY Change -56.64% -51.53% -24.67%
Income Tax $0.00 $3.000K $2.000K
% Of Pretax Income
Net Earnings -$447.0K -$1.288M -$2.653M
YoY Change -56.64% -51.45% -24.84%
Net Earnings / Revenue -10.93% -32.48% -64.11%
Basic Earnings Per Share $0.00 -$0.01 -$0.03
Diluted Earnings Per Share $0.00 -$0.01 -$0.03
COMMON SHARES
Basic Shares Outstanding 154.6M shares 152.1M shares 135.4M shares
Diluted Shares Outstanding 154.6M shares 152.6M shares 135.4M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.643M $1.690M $1.114M
YoY Change 44.25% 51.71% -54.72%
Cash & Equivalents $1.643M $1.690M $1.114M
Short-Term Investments
Other Short-Term Assets $412.0K $411.0K $3.217M
YoY Change -86.89% -87.22% 41.59%
Inventory $5.729M $5.836M $7.357M
Prepaid Expenses
Receivables $666.0K $611.0K $951.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.450M $8.548M $12.64M
YoY Change -30.75% -32.37% -15.89%
LONG-TERM ASSETS
Property, Plant & Equipment $399.0K $457.0K $698.0K
YoY Change -37.17% -34.53% -72.0%
Goodwill
YoY Change
Intangibles $251.0K $251.0K $1.485M
YoY Change -83.1% -83.1% -60.19%
Long-Term Investments
YoY Change
Other Assets $348.0K $401.0K $610.0K
YoY Change -37.52% -34.26% -37.95%
Total Long-Term Assets $1.193M $1.331M $3.119M
YoY Change -59.94% -57.33% -75.6%
TOTAL ASSETS
Total Short-Term Assets $8.450M $8.548M $12.64M
Total Long-Term Assets $1.193M $1.331M $3.119M
Total Assets $9.643M $9.879M $15.76M
YoY Change -36.48% -37.31% -43.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.623M $2.161M $2.473M
YoY Change 16.79% -12.62% 282.82%
Accrued Expenses $3.311M $3.537M $9.931M
YoY Change -65.94% -64.38% -2.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $952.0K
YoY Change -100.0%
Long-Term Debt Due $0.00 $28.00K $89.00K
YoY Change -100.0% -68.54% -97.03%
Total Short-Term Liabilities $6.061M $5.849M $13.56M
YoY Change -55.22% -56.85% -6.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $92.00K $125.0K $249.0K
YoY Change -57.99% -49.8% -92.0%
Total Long-Term Liabilities $92.00K $125.0K $249.0K
YoY Change -57.99% -49.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.061M $5.849M $13.56M
Total Long-Term Liabilities $92.00K $125.0K $249.0K
Total Liabilities $6.164M $5.985M $13.87M
YoY Change -55.39% -56.84% -22.24%
SHAREHOLDERS EQUITY
Retained Earnings -$83.70M -$83.30M -$84.30M
YoY Change -1.99% -1.19% 19.44%
Common Stock $15.00K $15.00K $14.00K
YoY Change 0.0% 7.14% 27.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.479M $3.894M $1.891M
YoY Change
Total Liabilities & Shareholders Equity $9.643M $9.879M $15.76M
YoY Change -36.48% -37.31% -43.34%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$447.0K -$1.288M -$2.653M
YoY Change -56.64% -51.45% -24.84%
Depreciation, Depletion And Amortization $58.00K $59.00K $343.0K
YoY Change -7.94% -82.8% 73.23%
Cash From Operating Activities -$19.00K $1.411M -$1.169M
YoY Change -96.53% -220.7% -61.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -28.00K -435.0K -156.0K
YoY Change -104.9% 178.85% -143.45%
NET CHANGE
Cash From Operating Activities -19.00K 1.411M -1.169M
Cash From Investing Activities 0.000
Cash From Financing Activities -28.00K -435.0K -156.0K
Net Change In Cash -47.00K 976.0K -1.325M
YoY Change -288.0% -173.66% -51.02%
FREE CASH FLOW
Cash From Operating Activities -$19.00K $1.411M -$1.169M
Capital Expenditures $0.00
Free Cash Flow -$1.169M
YoY Change -61.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154604000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154604000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
152104000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
152104000 shares
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-209000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-336000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-265000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1038000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1285000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2651000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4421000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4868000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1288000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2653000 usd
us-gaap Net Income Loss
NetIncomeLoss
4418000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4870000 usd
CY2023Q2 cvsi Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock
BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock
0 usd
CY2022Q2 cvsi Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock
BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock
920000 usd
cvsi Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock
BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock
0 usd
cvsi Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock
BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock
920000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1288000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1288000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3573000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3573000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4418000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
4418000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152599000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152599000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135414000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135414000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152353000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152353000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127104000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127104000 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-777000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
118000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
5706000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5047000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1288000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3894000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3543000 usd
CY2022Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
554000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1229000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
384000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
516000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2217000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4009000 usd
CY2022Q2 cvsi Stock Issued During Period Value Conversion Of Preferred Shares
StockIssuedDuringPeriodValueConversionOfPreferredShares
0 usd
CY2022Q2 cvsi Beneficial Conversion Charge For Preferred Stock Conversion
BeneficialConversionChargeForPreferredStockConversion
0 usd
CY2022Q2 cvsi Shareholders Equity Deemed Dividend
ShareholdersEquityDeemedDividend
0 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
389000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2653000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1891000 usd
us-gaap Net Income Loss
NetIncomeLoss
4418000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4870000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
118000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
860000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
153000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
662000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-159000 usd
cvsi Debt Discount And Interest Expense
DebtDiscountAndInterestExpense
112000 usd
cvsi Debt Discount And Interest Expense
DebtDiscountAndInterestExpense
1034000 usd
cvsi Employee Retention Credit Benefit
EmployeeRetentionCreditBenefit
0 usd
cvsi Employee Retention Credit Benefit
EmployeeRetentionCreditBenefit
1993000 usd
cvsi Noncash Lease Expense
NoncashLeaseExpense
53000 usd
cvsi Noncash Lease Expense
NoncashLeaseExpense
19000 usd
cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
-6171000 usd
cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
0 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
312000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
205000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-148000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1019000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-727000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1267000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2778000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-885000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-262000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-795000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2386000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1548000 usd
cvsi Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts
0 usd
cvsi Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts
554000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
954000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1117000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
190000 usd
us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
221000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1307000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1287000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1079000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-261000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
611000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1375000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1690000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1114000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000 usd
cvsi Increase Decrease In Convertible Note
IncreaseDecreaseInConvertibleNote
0 usd
cvsi Increase Decrease In Convertible Note
IncreaseDecreaseInConvertibleNote
-1030000 usd
cvsi Services Paid With Common Stock
ServicesPaidWithCommonStock
0 usd
cvsi Services Paid With Common Stock
ServicesPaidWithCommonStock
384000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
345000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2400000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1900000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-83300000 usd
cvsi Cares Act Tax Credit Received Under Relief Provision
CARESActTaxCreditReceivedUnderReliefProvision
2000000 usd
CY2022Q3 cvsi Cares Act Tax Credit Received Under Relief Provision
CARESActTaxCreditReceivedUnderReliefProvision
500000 usd
cvsi Cares Act Total Tax Credit Received Under Relief Provision
CARESActTotalTaxCreditReceivedUnderReliefProvision
2500000 usd
cvsi Cares Act Proceeds Received Under Relief Provision
CARESActProceedsReceivedUnderReliefProvision
2500000 usd
us-gaap Use Of Estimates
UseOfEstimates
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed financial statements and </span>accompanying notes. Actual results may differ from these estimates. Significant estimates include the valuation of intangible assets, inputs for valuing equity awards, valuation of inventory and assumptions related to revenue recognition.
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1020000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1402000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3966000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4138000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8114000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8585000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
3246000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3563000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1188000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1980000 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
5836000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
6563000 usd
CY2022Q2 us-gaap Inventory Write Down
InventoryWriteDown
100000 usd
us-gaap Inventory Write Down
InventoryWriteDown
200000 usd
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
CY2023Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
522000 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
6694000 usd
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1409000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1447000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1606000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1549000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3537000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9690000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
0 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
0 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P23M
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
68000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
139000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
59000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
266000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
248000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
123000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
125000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
248000 usd
CY2022Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
151772 usd
CY2022Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
3751971 shares
CY2022Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.04
CY2022Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
7172244 shares
us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
13976525 shares
us-gaap Interest Expense Debt
InterestExpenseDebt
600000 usd
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
127000 usd
CY2022Q3 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
50000 usd
CY2023Q2 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
28000 usd
CY2022Q4 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
1223000 usd
cvsi Caresact Proceeds To Be Remitted To Lender Minimum
CARESACTProceedsToBeRemittedToLenderMinimum
1000000 usd
CY2022Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
200000000 shares
CY2022Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
800000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
790000000 shares
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
10000000 shares
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
700000 usd
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
600000 usd
CY2022Q1 cvsi Sale Of Stock Deduction From Proceeds Related To Agents Fees And Other Offering Expenses
SaleOfStockDeductionFromProceedsRelatedToAgentsFeesAndOtherOfferingExpenses
100000 usd
CY2022Q1 cvsi Preferred Stock Par Or Stated Value Per Share Subjected To Conversion
PreferredStockParOrStatedValuePerShareSubjectedToConversion
1000
CY2022Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
10000000 shares
CY2022Q1 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
0.07
CY2022Q1 cvsi Class Of Warrants Or Rights Fair Value Recorded As Additional Offering Cost
ClassOfWarrantsOrRightsFairValueRecordedAsAdditionalOfferingCost
100000 usd
CY2022Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
10000000 shares
CY2022Q1 cvsi Preferred Stock Number Of Votes Per Share
PreferredStockNumberOfVotesPerShare
170000 vote
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
800000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
790000000 shares
CY2022Q2 cvsi Beneficial Conversion Feature Deemed Dividend Debit Credit Upon Conversion Of Preferred Stock
BeneficialConversionFeatureDeemedDividendDebitCreditUponConversionOfPreferredStock
900000 usd
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10750000 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10750000 shares
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
300000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19831000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.46
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y6M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
7700000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.05
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3100000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.46
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24431000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
16440000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y7M6D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
24431000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y10M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.360
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.320
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.038
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y14D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41931000 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46033000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41931000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
46033000 shares
CY2022Q2 cvsi Loss Contingency Issuance Of Interim Awarding Related To Purchase Of Psl And Other Advance Payments
LossContingencyIssuanceOfInterimAwardingRelatedToPurchaseOfPSLAndOtherAdvancePayments
300000 usd
CY2022Q2 cvsi Termination Severance And Other Post Termination Compensation And Benefits Under His Employment Agreement
TerminationSeveranceAndOtherPostTerminationCompensationAndBenefitsUnderHisEmploymentAgreement
600000 usd
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
300000 usd
CY2023Q1 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
17481 usd
cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0 usd
CY2022Q2 cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0 usd
CY2023Q2 cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0 usd
cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0 usd

Files In Submission

Name View Source Status
cvsi-20230630_htm.xml Edgar Link completed
cvsi-20230630_cal.xml Edgar Link unprocessable
0001510964-23-000032-index-headers.html Edgar Link pending
0001510964-23-000032-index.html Edgar Link pending
0001510964-23-000032.txt Edgar Link pending
0001510964-23-000032-xbrl.zip Edgar Link pending
cvsi-20230630.htm Edgar Link pending
cvsi-20230630.xsd Edgar Link pending
cvsi-2023630xex311.htm Edgar Link pending
cvsi-2023630xex312.htm Edgar Link pending
cvsi-2023630xex321.htm Edgar Link pending
cvsi-2023630xex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nog2023equityincentiveplan.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
cvsi-20230630_def.xml Edgar Link unprocessable
cvsi-20230630_pre.xml Edgar Link unprocessable
cvsi-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending